Innovative translational research in leukemia is critically dependent on the availability of funding for pilot projects. The Leukemia SPORE Developmental Research Program (DRP) will be a source of seed funding with the following goals: 1) encourage and explore innovative translational research ideas which focus on leukemia research;and 2) encourage successful researchers working in other fields to focus their expertise toward the development of innovative translational projects in leukemia research. Both laboratory and clinical research projects are eligible for funding, provided that they are translational in nature. The purpose of the SPORE Developmental Research Program is to develop translational research projects that should result in clinically-testable hypotheses aimed at improving prognosis for patients with leukemia. Support of $100,000 from the SPORE and $100,000 from matching institutional support as described in the letter of Institutional Commitment will provide a total of $200,000 per year available through the Developmental Research Program for approximately 4 to 5 projects (approximately $50,000 per project). Funding will be awarded for 1 year;with satisfactory review from the respective advisory committees and progress on the individual projects'specific aims, the funding could be carried over for an additional year. The specific objectives of the Developmental Research Program are to: 1. Publicize the availability of funds for pilot translational leukemia research studies. Identify through this mechanism innovative projects with significant potential for improving leukemia therapy and prognosis. 2. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE. 3. Enhance the communication between the SPORE leaders and outside investigators to encourage the development of innovative translational strategies in leukemia. 4. Ensure program flexibility so that developmental projects that show promise can be: 1) funded for a second year;2) encouraged to apply for peer-reviewed funding (i.e. R01);or 3) expanded to become full SPORE projects. Lay Description: Innovative translational research in leukemia is critically dependent on the availability of funding for pilot projects. The Leukemia SPORE Developmental Research Program will be a source of seed funding with the following goals: 1) encourage and explore innovative translational research ideas which focus on leukemia research;and 2) encourage successful researchers working in other fields to focus their expertise toward the development of innovative translational projects in leukemia research

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-08
Application #
8141965
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$126,197
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 487 publications